Back to People
Dana Aboud

Dana Aboud Associate - Not admitted in District of Columbia; admitted in Pennsylvania. Application for admission to the District of Columbia bar filed; working under the direct supervision of an enrolled, active member of the D.C. bar.

Save current page as PDF
Washington, D.C. T +1 202 857 1715 F fax +1 202 828 3345
vCard

Dana focuses her practice on securities and other corporate governance matters.

Dana received her law degree from Thomas R. Kline School of Law of Duquesne University (“Duquesne-Kline Law”), graduating magna cum laude.

While at Duquesne-Kline Law, Dana served as a production editor for the Duquesne Law Review and served as a teaching assistant in Duquesne-Kline’s nationally ranked Legal and Research Writing program. Dana further served as a research assistant for the Dean of Academic affairs, a teaching assistant for Constitutional Law, and was the vice president of the First Generation (Law) Student Society. Dana was awarded the Robert Scott Memorial Award for her demonstrated commitment to equal justice and advancing Diversity and Inclusion in the legal profession, as well as CALI Excellence for Future Awards (highest grade) in the courses of Legal Research and Writing and Energy Regulation for her academic merit.

Prior to law school, Dana received her B.A. in Economics and Political Science from the University of Pittsburgh.

In between her undergraduate studies and time in law school, Dana worked in analyst roles at a multinational electrical distribution company and a Fortune 500 American financial institution, respectively.

Experience

  • Representation of one of the largest energy and utility companies in the U.S. in connection with its tender offer to purchase for cash any and all of its outstanding 4.65% series B Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock.
  • Representation of Titan Partners Group, a division of American Capital Partners, as sole bookrunner, in connection with an $11.0 million public offering of common stock and pre-funded warrants by Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company leading the discovery and development of next generation allosteric therapies.
  • Representation of Newbridge Securities Corporation, as exclusive placement agent, in connection with a $3.4 million registered direct offering of ordinary shares and pre-funded warrants by Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq:IINN), an innovative medical technology company in the life support arena.

News

More News